JLE

Médecine

MENU

Osteoporosis 2015: what's new? Volume 11, issue 4, Avril 2015

Author
Hôpital Gériatrique de L'Isle-Adam ­Parmain dletonturier@chantepiemancier.fr

Bisphosphonates are effective on osteoporotic fractures, but in patients over 75 years old, denosumab is even more effective because of its lack of bone retention. Teriparatide is indicated for spinal osteoporosis beginning at the diagnosis of at least 2 clinical vertebral settlements and for a total duration of 18 months. Future bone formation agents are represented by two anti-sclerostines antibodies. The availability of new products with different mechanisms of action announced the upcoming arrival of new biotherapy or immunotherapies that would ensure optimal primary prevention of the occurrence of a first fracture. The key element remains adherence.